Form 4: Ocular Therapeutix CDO Sells Shares for Tax Obligations

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 9,653 shares of common stock at a weighted average price of $11.03 to cover tax obligations from restricted stock unit vesting.

Summary

• Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc. (OCUL), reported a sale of common stock.
• A total of 9,653 shares were sold on October 2, 2025.
• The shares were sold at a weighted average price of $11.03 per share, with prices ranging from $10.99 to $11.0697.
• The transaction was executed pursuant to a durable automatic sale instruction (Rule 10b5-1(c) plan) adopted on April 9, 2024.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) on October 1, 2025.
• This sale was not a discretionary trade by the reporting person.
• Following the transaction, Peter Kaiser beneficially owns 194,440 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is neutral as it is a non-discretionary sale to cover tax obligations from RSU vesting, a routine event for executives.

Positives

• The sale was non-discretionary, executed under a pre-arranged Rule 10b5-1 plan, indicating it was not based on new material non-public information.
• The transaction was for a routine purpose of covering tax withholding obligations related to RSU vesting.

Negatives

• A reduction in insider ownership, even for tax purposes, slightly decreases management's direct equity stake in the company.

Risks

• No specific risks related to the company's operations or financial health were mentioned in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing.

Management Comments

• Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 1, 2025.
• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This is a routine insider transaction common across all industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive dynamics.

Comparison to Industry Standards

• Not applicable. This filing reports a standard insider transaction for tax purposes, which is a common practice for executives receiving equity compensation across publicly traded companies.

Stakeholder Impact

• Shareholders: Minor, as it's a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• No specific future actions, events, or milestones for the company were mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary sale of shares by a Chief Development Officer to cover tax obligations arising from restricted stock unit vesting. Such transactions, executed under a pre-arranged 10b5-1 plan, are common and generally do not reflect a change in the insider's view of the company's prospects. Therefore, this filing alone does not provide a basis for altering an investment thesis, and a "hold" recommendation is appropriate.

Keywords

OCULAR THERAPEUTIX, OCUL, Peter Kaiser, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, 10b5-1 Plan, Chief Development Officer